News – Page 33 – Global Reach Health

April 25, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Veklury-Approved-to-Treat-COVID-19-in-Younger-Patient-Population-480x360.jpg" class="scale-with-grid wp-post-image" alt="Veklury-Approved-to-Treat-COVID-19-in-Younger-Patient-Population" decoding="async" />

Veklury-Approved-to-Treat-COVID-19-in-Younger-Patient-Population

Veklury Approved to Treat COVID-19 in Younger Patient Population

April 25, 2022 – Veklury^® (remdesivir) is now indicated to treat patients as young as 28 days and weighing at least 3kg (7 pounds) who have positive results of direct SARS-CoV-2

April 22, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Pfizer-Recalls-Five-Lots-of-Accupril-480x360.jpg" class="scale-with-grid wp-post-image" alt="Pfizer-Recalls-Five-Lots-of-Accupril" decoding="async" />

Pfizer-Recalls-Five-Lots-of-Accupril

Pfizer Recalls Five Lots of Accupril

April 22, 2022 – Pfizer has recalled five lots of Accupril^® (quinapril HCl) tablets due to the presence of a nitrosamine identified as above the established acceptable daily intake

April 21, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Zerbaxa-Now-Indicated-for-Children-480x360.jpg" class="scale-with-grid wp-post-image" alt="Zerbaxa-Now-Indicated-for-Children" decoding="async" />

Zerbaxa-Now-Indicated-for-Children

Zerbaxa Now Indicated for Children

April 21, 2022 – Zerbaxa^® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections

April 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Ardelyx-Launches-Irritable-Bowel-Syndrome-Treatment-Ibsrela-480x360.jpg" class="scale-with-grid wp-post-image" alt="Ardelyx-Launches-Irritable-Bowel-Syndrome-Treatment-Ibsrela" decoding="async" />

Ardelyx-Launches-Irritable-Bowel-Syndrome-Treatment-Ibsrela

Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela

April 4, 2022 – Several years following FDA approval, Ibsrela^® (tenapanor) oral tablets are now available to treat irritable bowel syndrome with constipation (IBS-C) in adults

April 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Single-Batch-of-Lantus-Generic-Recalled-480x360.jpg" class="scale-with-grid wp-post-image" alt="Single-Batch-of-Lantus-Generic-Recalled" decoding="async" />

Single-Batch-of-Lantus-Generic-Recalled

Single Batch of Lantus Generic Recalled

March 29, 2022 – Teva Pharmaceuticals has recalled lot 31329657B of IDArubicin Hydrochloride Injection USP 5mg/5mL vials. An internal inspection found one vial contained silica

April 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders-480x360.jpg" class="scale-with-grid wp-post-image" alt="Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders" decoding="async" />

Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders

Imcivree Approved in Treatment of Two Rare Genetic Disorders

April 14, 2022 – The U.S. FDA has approved Imcivree^® (setmelanotide) for treatment of obesity and control of hunger in patients who are at least six years old and have Bardet-Biedl

April 13, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Avastin-Biosimilar-Alymsys-Granted-Approval-480x360.jpg" class="scale-with-grid wp-post-image" alt="Avastin-Biosimilar-Alymsys-Granted-Approval" decoding="async" />

Avastin-Biosimilar-Alymsys-Granted-Approval

Avastin Biosimilar Alymsys Granted Approval

April 13, 2022 – Amneal has received FDA approval for Alymsys^® (bevacizumab-maly) intravenous injection, a biosimilar to Genentech’s Avastin^®

April 11, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Xigduo-XR-Receives-New-Indication-for-Kidney-Disease-480x360.jpg" class="scale-with-grid wp-post-image" alt="Xigduo-XR-Receives-New-Indication-for-Kidney-Disease" decoding="async" />

Xigduo-XR-Receives-New-Indication-for-Kidney-Disease

Xigduo XR Receives New Indication for Kidney Disease

April 11, 2022 – Xigduo^® XR (dapagliflozin/metformin) has received a new indication for one of its active pharmaceutical ingredients (APIs), dapagliflozin, to reduce the risk of